BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.

To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link

Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at https://biontech.com/. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.

About BioNTech

Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, OncoC4, Pfizer and Regeneron.

For more information, please visit www.BioNTech.com.

CONTACTS

Investor Relations
Victoria Meissner, M.D.
+1 617 528 8293
Investors@biontech.de

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de

 

Staff

Recent Posts

Unlearn Appoints Its First Vice President of Product

Kwame Marfo brings more than 15 years of experience at the intersection of life sciences,…

2 hours ago

AdvancedMD Partners with EirSystems, Offering Private Practices an Innovative eMAR Platform to Manage Prescriptions

EIRMAR, EirSystem’s electronic medication administration records platform, delivers advanced medication management functionality to help providers…

2 hours ago

Echo Responds to Misinformation with Science: Hydrogen Water Bottles Outperform Tablets in Safety, Efficacy, and Value

SALT LAKE CITY--(BUSINESS WIRE)--Echo, the global leader in hydrogen health technology, is responding forcefully to…

2 hours ago

Echo Responds to Misinformation with Science: Hydrogen Water Bottles Outperform Tablets in Safety, Efficacy, and Value

SALT LAKE CITY--(BUSINESS WIRE)--Echo, the global leader in hydrogen health technology, is responding forcefully to…

2 hours ago

Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption

Investors choose to redeem or convert the majority of Series C and Series D Preferred…

2 hours ago

LogicMark, Inc. to Announce Second Quarter 2025 Financial Results on August 12, 2025

LOUISVILLE, Ky., July 29, 2025 (GLOBE NEWSWIRE) -- LogicMark, Inc. (OTC: LGMK), a provider of…

2 hours ago